2007-07-04
Affibody appoints Erik Walldén as CEO
STOCKHOLM, Sweden, July 4, 2007. The Swedish biotech company Affibody AB has appointed Erik Walldén as CEO and has elected two new members of the Board of Directors, Peter Buhl Jensen, MD, PhD and Gillies O’Bryan-Tear, MD. This represents a significant reinforcement of Affibody´s management competence.
Erik Walldén will assume his new role on July 15. He has an extensive experience from the biotech supply industry. Most recently he served as President and CEO of Biacore AB. Walldén has previously held several senior positions in different companies in R&D, Marketing and Sales, in Sweden as well as internationally. Erik Walldén was formerly CEO of Pyrosequencing AB. Walldén has an education in analytical chemistry and biochemistry from University of Uppsala. Walldén will succeed Ulf Boberg who assumes a new position as SVP, Clinical Development and Business Development.
“I am extremely pleased that we have managed to attract a CEO with such an extensive experience from the biotech supply industry. Affibody is making significant progress and has ongoing projects for cancer diagnostics in clinical development. Erik Walden’s primary task will be to further advance and commercialize the company’s R&D portfolio focusing on molecular imaging and targeted therapeutics”, says Håkan Åström, Chairman, Affibody AB.
Peter Buhl Jensen is CEO and co-founder of TopoTarget AS. Buhl Jensen has significant management experience in cancer research and translational drug development. He is a specialist in internal medicine and has a PhD in preclinical cancer therapeutics evaluation. He has published more than 80 papers on cancer and its treatment.
Dr Gillies O’Bryan-Tear is a consultant and was previously VP Global Clinical R&D, at GlaxoSmithKline Biologicals. He has a broad international R&D experience from several senior roles within the global pharmaceutical industry. Gillies is a UK trained physician and holds an MBA.
“The new members of the Board bring significant international experience from clinical research, development and commercialization”, comments Håkan Åström.